395 results on '"Foster, G. R."'
Search Results
2. High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital : should we be screening for HCV in ED attendees?
3. Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III)
4. Sofosbuvir and velpatasvir with or without voxilaprevir in direct‐acting antiviral‐naïve chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3
5. Supplement to: Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection
6. Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin
7. Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: the “Going Viral” campaign
8. Humid Regions
9. Beyond the USLE: Advancements in Soil Erosion Prediction
10. Processes of Soil Erosion by Water
11. Sediment Yield from Farm Fields: The Universal Soil Loss Equation and Onfarm 208 Plan Implementation
12. Transferability of U.S. Technology for Prediction and Control of Erosion in the Tropics
13. Combination Treatment For Hepatitis C Is Not Being Given
14. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact
15. Systematic analysis of funding awarded for viral hepatitis-related research to institutions in the United Kingdom, 1997–2010
16. Management of Chronic Hepatitis C: Clinical Audit of Biopsy Based Management Algorithm
17. Sofosbuvir-based regimens are associated with high SVR rates across genotypes and among patients with multiple negative predictive factors
18. Review article: 2014 UK consensus guidelines – hepatitis C management and direct-acting anti-viral therapy
19. Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naïve patients: Final results from startverso1, a randomised, double-blind, placebo-controlled phase III trial
20. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes
21. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin
22. Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3
23. OC-024 Development and validation of a novel capture-fusion model for HCV replication
24. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients
25. OP12 Similar Svr Rates In Il28b Cc, Ct Or Tt prior relapser, partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the Realize Study
26. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection
27. Patients with m2 antibodies: what diagnosis and follow-up are they given?
28. Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin
29. Quality of life considerations for patients with chronic hepatitis C
30. Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use
31. Editorial
32. Editorial
33. Editorial
34. Interferon-α2a is sufficient for promoting dendritic cell immunogenicity
35. Insulin Resistance Plays a Significant Role in Liver Fibrosis in Chronic Hepatitis C and in the Response to Antiviral Therapy
36. An unusual form of autoimmune hepatitis in young Somalian men
37. Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C
38. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C
39. Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy – patientsʼ views of early cessation of therapy
40. Negative correlation between intrahepatic expression of hepatitis C antigens and apoptosis despite high-level expression of Fas and HLA antigens
41. Review article: Pegylated interferons: chemical and clinical differences
42. Improving hepatitis C services across the UK: response to a walk-in HCV testing service
43. Cost-Effectiveness of Combination Peginterferon α-2a and Ribavirin Compared With Interferon α-2b and Ribavirin in Patients With Chronic Hepatitis C
44. Role of interferons in dendritic cells activation—the immune millieu modifies the Th1/Th2 outcome
45. Management of chronic hepatitis C – time for a change?
46. Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: uptake and acceptability of named antenatal testing
47. Editorial
48. Editorial
49. Hepatitis C virus infection: quality of life and side effects of treatment
50. Are all Type I human interferons equivalent?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.